Theo Tarver

Theo is a biologist in the Platform group with experience in assay development and the study of cancer therapies. He received a B.S. in Biology, with a minor in Biochemistry, at the University of San Francisco. At Roche Molecular Systems, he participated in the research and development of medical diagnostic assays for targets such as HIV and genetic mutations implicated in lung cancer. Then, at UCSF under Dr. Catherine Smith, he researched mechanisms of response and resistance to targeted drug therapy for acute myeloid leukemia. Outside of the lab, Theo enjoys golfing, hiking, and following his Bay Area sports teams.


Smith, C.C., Viny, A.D., Massi, E., Kandoth, C., Socci, N.D., Rapaport, F., Najm, M., Medina-Martinez, J.S.,Papaemmanuil, E. Tarver, T.C., Hsu, H.H., Le, M.H., West, B., Bollag, G., Taylor, B.S., Levine. R.L., & Shah, N.P. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research (2021) 27 (14), 14, 4003-4011

Tarver, T., Hill, J. Rahmat, L., Perl, A., Bahceci, E., Mori, K., & Smith, C C. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv (2020) 4 (3): 514–524.

Smith, C. C., Paguirigan, A., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T., Chin, C. S., Asthana, S., Olshen, A., Travers, K. J., Wang, S., Levis, M. J., Perl, A. E., Radich, J. P., & Shah, N. P. (2017). Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood (2017), 130 (1), 48–58.

View LeadershipView Board of DirectorsView Full TeamView Scientific Advisory Board